Literature DB >> 16338086

Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders.

V Papadopoulos1, L Lecanu, R C Brown, Z Han, Z-X Yao.   

Abstract

The peripheral-type benzodiazepine receptor is a mitochondrial protein expressed at high levels in steroid synthesizing tissues, including the glial cells of the brain. Peripheral-type benzodiazepine receptor binds cholesterol with high affinity and is a key element of the cholesterol mitochondrial import machinery responsible for supplying the substrate cholesterol to the first steroidogenic enzyme, thus initiating and maintaining neurosteroid biosynthesis. Neurosteroid formation and metabolism of steroid intermediates are critical components of normal brain function. Peripheral-type benzodiazepine receptor also binds with high affinity various classes of compounds. Upon ligand activation peripheral-type benzodiazepine receptor-dependent cholesterol transport into mitochondria is accelerated leading in increased formation of neuroactive steroids. These steroids, such as allopregnanolone, have been shown to be involved in various neurological disorders, such as anxiety and mood disorders. Thus, peripheral-type benzodiazepine receptor drug ligand-induced neuroactive steroid formation offers a means to regulate brain dysfunction. Peripheral-type benzodiazepine receptor basal expression is upregulated in a number of neuropathologies, including gliomas and neurodegenerative disorders, as well as in various forms of brain injury and inflammation. In Alzheimer's disease pathology neurosteroid biosynthesis is altered and a decrease in the intermediate 22R-hydroxycholesterol levels is observed. This steroid was found to exert neuroprotective properties against beta-amyloid neurotoxicity. Based on this observation, a stable spirostenol derivative showing to display neuroprotective properties was identified, suggesting that compounds developed based on critical intermediates of neurosteroid biosynthesis could offer novel means for neuroprotection. In conclusion, changes in peripheral-type benzodiazepine receptor and neurosteroid levels are part of the phenotype seen in neuropathology and neurological disorders and offer potential targets for new therapies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16338086     DOI: 10.1016/j.neuroscience.2005.05.063

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  76 in total

Review 1.  Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states.

Authors:  Amani Batarseh; Vassilios Papadopoulos
Journal:  Mol Cell Endocrinol       Date:  2010-06-30       Impact factor: 4.102

2.  Translocator protein 18 kDa negatively regulates inflammation in microglia.

Authors:  Keun-Ryung Bae; Hyun-Jung Shim; Deebika Balu; Sang Ryong Kim; Seong-Woon Yu
Journal:  J Neuroimmune Pharmacol       Date:  2014-04-01       Impact factor: 4.147

Review 3.  Pregnane xenobiotic receptors and membrane progestin receptors: role in neurosteroid-mediated motivated behaviours.

Authors:  C A Frye; C J Koonce; A A Walf
Journal:  J Neuroendocrinol       Date:  2013-11       Impact factor: 3.627

4.  4'-Chlorodiazepam Protects Mitochondria in T98G Astrocyte Cell Line from Glucose Deprivation.

Authors:  Eliana Baez; Gina Paola Guio-Vega; Valentina Echeverria; Daniel Andres Sandoval-Rueda; George E Barreto
Journal:  Neurotox Res       Date:  2017-04-13       Impact factor: 3.911

Review 5.  Imaging microglial activation during neuroinflammation and Alzheimer's disease.

Authors:  Sriram Venneti; Clayton A Wiley; Julia Kofler
Journal:  J Neuroimmune Pharmacol       Date:  2008-12-04       Impact factor: 4.147

Review 6.  Molecular imaging of microglia/macrophages in the brain.

Authors:  Sriram Venneti; Brian J Lopresti; Clayton A Wiley
Journal:  Glia       Date:  2012-05-21       Impact factor: 7.452

7.  New fluorescent probes targeting the mitochondrial-located translocator protein 18 kDa (TSPO) as activated microglia imaging agents.

Authors:  Nunzio Denora; Valentino Laquintana; Adriana Trapani; Hiromi Suzuki; Makoto Sawada; Giuseppe Trapani
Journal:  Pharm Res       Date:  2011-08-05       Impact factor: 4.200

8.  Investigation Into the Effects of Tenilsetam on Markers of Neuroinflammation in GFAP-IL6 Mice.

Authors:  Erika Gyengesi; Huazheng Liang; Christopher Millington; Sandra Sonego; Daniel Sirijovski; Dhanushka Gunawardena; Karthik Dhananjayan; Madhuri Venigalla; Garry Niedermayer; Gerald Münch
Journal:  Pharm Res       Date:  2018-01-05       Impact factor: 4.200

9.  Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain.

Authors:  M Cosenza-Nashat; M-L Zhao; H-S Suh; J Morgan; R Natividad; S Morgello; S C Lee
Journal:  Neuropathol Appl Neurobiol       Date:  2008-12-11       Impact factor: 8.090

10.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.